Keryx Biopharma (KERX) Initiates Phase 3 Registration of KRX-0401 (AEZS)
Tweet Send to a Friend
Keryx Biopharmaceuticals, Inc. (NASDAQ: KERX) announced today the initiation of a Phase 3 registration clinical trial for KRX-0401 (perifosine), the ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
